Psilocybin-Research.com Research. Clarity. Progress.
Preparing publication tracker
Psilocybin-Research.com Research. Clarity. Progress.
Admin

Psilocybin Research Publication Tracker

Search, analyze, export, and monitor psilocybin and psilocin literature across peer-reviewed papers, preprints, reviews, protocols, and clinical trials.

Database up to date Last update: Jul 2, 2026 06:57 UTC
Indexed records 3,812 SQLite literature index
Published 3,046 Peer-reviewed / formal records
Preprints 479 Marked as not peer reviewed
Clinical trials 287 ClinicalTrials.gov records
Source coverage
Source Count Share Status
Europe PMC 2,654 69.6% Active
PubMed 309 8.1% Active
ClinicalTrials.gov 287 7.5% Active
PsyArXiv 218 5.7% Active
Crossref 168 4.4% Active
bioRxiv 142 3.7% Active
medRxiv 34 0.9% Active
Publication growth 2,994 records since 2020
Annual records Cumulative line
3,812Total Publications
3,679Psilocybin Records
538Psilocin Records
Search Matches
258Journals
66Research Topics

Research search

Reset all
Substances
Date range quick select

Advanced filters

Refine the current publication search without losing source and evidence-status context.

Use these only when the initial search is too broad. Filters are source-aware and preserve preprint, clinical trial, review, protocol, and published distinctions.

Evidence status
Current display No search or filter specified Showing the latest indexed records until a keyword search is submitted.

Latest Publications

Most recently published records currently stored in SQLite.

1-20
Last updated: Jul 2, 2026 06:57 UTC
Checking for newly published papers…

Contribution of the Serotonin 5-HT2A Receptor to the Therapeutic Effect of Psilocin on Social Behavior Deficits in Mice Repeatedly Exposed to Social Defeat Stress

Neuropsychopharmacology Reports · 2026-08-31

Ibi Daisuke, Takaba Rika, Yoshida Keisuke, Kawase Ririna, Kitagawa Hiroko, Matsushita Momoko, Ito Kana, Uno Shoya, Nishimura Fumiya, Kitagaki Shinji, Hiramatsu Masayuki

Crossref Published psilocybinpsilocin DepressionAnxietyReceptor PharmacologyResilienceAnimal StudyTreatment-Resistant Depression Animal Study

Modeled Long-Term Effects of Psilocybin on Dynamic Activity and Effective Connectivity of Fronto-Striatal-Thalamic Circuits

Human Brain Mapping · 2026-06-30

Pasquini Lorenzo, Vohryzek Jakub, Escrichs Anira, Perl Yonatan Sanz, Ponce-Alvarez Adrian, Idesis Sebastian, Girn Manesh, Roseman Leor, Mitchell Jennifer M., Gazzaley Adam, Kringelbach Morten, Nutt David J., Lyons Taylor, Carhart-Harris Robin L., Deco Gustavo

Crossref Published psilocybin DepressionEating DisordersBrain ImagingMechanism of ActionReceptor PharmacologyHealthy Volunteers Other

Blinding Integrity in Psychedelic Randomized Clinical Trials: A Systematic Review.

JAMA psychiatry · 2026-06-30

Orsini DK, Wong S, Di Luch S, Chan B, Vasudeva S, Lovell GFM, Le GH, Jones BDM, Chisamore N, Mollica A, Johnson DE, Kaczmarek ES, Goel A, Burke MJ, Mansur R, McIntyre RS, Husain MI, Rosenblat JD

PubMed Published psilocybin Clinical TrialRandomized Controlled TrialSystematic ReviewReview Article Randomized Controlled Trial
Page 4 of 138

Psilocybin for PTSD With or Without Psychotherapy: A Pilot Study of Safety and Efficacy

The proposed open-label, controlled study at the Johns Hopkins Center for Psychedelic and Consciousness Research (CPCR) will test the following primary hypotheses in adult patients with chronic PTSD who are currently taking a serotonin reuptake inhibitor: psilocybin therapy will be feasible and safe for participants, significantly remediate PTSD symptoms, an...

ClinicalTrials.gov 2026-06-21 Johns Hopkins University
ClinicalTrials.gov CLINICAL TRIAL psilocybin PTSDReceptor PharmacologyConsciousnessWellbeingMystical ExperienceRandomized Controlled TrialHealthcare WorkersSafety Randomized Controlled Trial Post Traumatic Stress DisorderPsilocybin

Psilocybin-assisted Existential, Attachment and RelationaL (PEARL) Therapy for Patients With Advanced Cancer: A Phase II Open-Label Trial

The PEARL Pilot is a phase II open-label trial. Participants will receive a single high-dose (25 mg) of psilocybin in the context of Psilocybin-assisted Existential, Attachment and RelationaL (PEARL) therapy. Individuals with advanced cancer often experience high levels of distress due to physical suffering, difficult treatment decisions, social isolation, a...

ClinicalTrials.gov 2026-06-21 University Health Network, Toronto
ClinicalTrials.gov CLINICAL TRIAL psilocybin End-of-Life DistressClinical TrialSafety Clinical Trial Advanced CancerStage IV Solid Tumor Cancer

Sex-Specific Effects of Psilocybin Versus Escitalopram on Anxiety and Anhedonia: A Bayesian Reanalysis of Antidepressant Treatment Outcomes

Abstract Rationale: Major depressive disorder (MDD) shows marked sex differences in prevalence, symptomatology, and treatment response. However, women remain underrepresented in many clinical trials, and sex-specific treatment outcomes are rarely examined. Objectives This study reanalyzed data from a randomized controlled trial comparing psilocybin and escit...

Research Square 2026-06-18 Frick A, Blest-Hopley G, Grin M, Erritzoe D, Nutt D, Carhart-Harris R.
Europe PMC PREPRINT (not peer reviewed) psilocybin DepressionAnxietyWellbeingClinical TrialRandomized Controlled TrialDrug Interactions Randomized Controlled Trial

Psilocybin-assisted therapy in treatment-resistant depression: rapid remission, uncertain durability, and the next phase of clinical evidence

Treatment-resistant depression (TRD) remains a major clinical challenge and is typically defined as the persistence of depressive symptoms despite at least two adequate antidepressant trials. Individuals with TRD experience substantial morbidity, impaired functioning, and elevated suicide risk, highlighting the need for therapeutic strategies beyond incremen...

Annals of Medicine & Surgery 2026-06-18 Sabani Astrit, Khatak Adnan
Crossref Published psilocybin DepressionReceptor PharmacologyAgingTreatment-Resistant DepressionSafety Clinical Trial

Psychedelic Use, Microdosing, Motives, and Information and Product Sources Among Young Adults in the United States.

Given the increases in psychedelic use, we examined correlates of psychedelic use and use motives among US young adults. In 2025, adults ages 18-34 (n = 3,227; Mage = 26.38, ~50% past-month cannabis use by design) completed an online survey. Multivariable regression assessed sociodemographics, mental health, and adverse childhood events (ACEs) in relation to...

Unknown journal 2026-06-18 Berg CJ, McCready DM, LoParco CR, Schubel LC, Romm KF, Thakkar S, Williams J, Cavazos-Rehg PA, Yang YT.
Europe PMC Published psilocybin DepressionAnxietyMicrodosingObservational Study Observational Study

Marketing by online tobacco retailers: An observational cross-sectional study.

IntroductionUnderstanding retailer advertising has been identified as critical for developing effective policies to reduce tobacco product use, as these forms of advertising are among the tobacco industry's largest expenditures. Online retailer marketing has grown rapidly, and in this study, we sought to describe the marketing practices of these retailers.Me...

Unknown journal 2026-06-18 Apollonio DE, Dennehy CE, Tsourounis C, Wakefield T.
Europe PMC Published psilocybin AddictionObservational Study Observational Study

Therapeutic advances in fibromyalgia: one year in review 2026.

Fibromyalgia (FM) is a chronic nociplastic pain syndrome characterised by widespread pain, fatigue, sleep disturbances and cognitive impairment, with a significant impact on health-related quality of life (HRQoL). Despite the availability of several therapeutic options, management remains challenging and often requires a personalised and multidimensional app...

Unknown journal 2026-06-17 Bazzichi L, Di Carlo M, Salaffi F, Farah S, Porta F, Ablin JN, Varrassi G, Galli F, Fornasari D, Carotti M, Alciati A, Pellegrino G, Batticciotto A, Lucini D, Casale R, Di Franco M, Sarzi-Puttini P, Iannuccelli C, Pain Study Group of the Italian Society of Rheumatology (SIR).
Europe PMC Published psilocybin Chronic PainMitochondrial FunctionOxidative StressWellbeingEmotional ProcessingReview ArticleInflammation Clinical Trial HumansFibromyalgia

DESI-MSI-Based Multi-Organ Distribution Mapping of Psilocin in Zebrafish.

Psilocybin, a psychedelic drug with reported anxiolytic and antidepressant potential, is rapidly metabolized to its active metabolite psilocin. However, a lack of adequate toxicity studies and tissue distribution studies currently restricts its development and application. This study combined behavioral assays in zebrafish with desorption electrospray ioniza...

Unknown journal 2026-06-17 Dong M, Zhang Y, Cao M, Shi T, Li L, Zong X, Wang C.
Europe PMC Published psilocybinpsilocin Brain ImagingAgingSafetyToxicity Other BrainAnimals

Community engagement as a foundation for implementation research for group psilocybin assisted therapy in New Mexico

Informed by a community engagement process, we have developed a pragmatic, open-label, hybrid feasibility-implementation study of Group Psilocybin-Assisted Therapy (GPAT) for post-traumatic stress disorder (PTSD). As psychedelic-assisted therapies begin to enter the broader mental health arena, engaging communities in the design of research and care models i...

Frontiers in Public Health 2026-06-16 Leeman Lawrence, Armstrong Maya, Menashi Dara, Nayo-Washington Hanifa, Marseille Elliot, Herrera Janus, Romero Crystal, Page-Reeves Janet
Crossref Published psilocybin PTSDAgingClinical TrialVeteransHealthcare WorkersSafety Clinical Trial

Short- and Long-Acting Psychedelics: Structure-Activity Relationships, Pharmacology, and Implications for Neuropsychiatric Therapeutics.

Psychedelics have re-emerged as promising therapeutics for neuropsychiatric disorders, including depression, anxiety, post-traumatic stress disorder, and substance use disorders. While their beneficial effects are largely attributed to serotonin 2A (5-HT2A) receptor activation, psychedelics exhibit substantial diversity in chemical structure, receptor bindin...

ACS chemical neuroscience 2026-06-16 Bhat A, Zolali E, Sakib MA, Rahimian M, McMahon LR, German N, Obeng S
PubMed Published psilocybin DepressionAnxietyPTSDAddictionPharmacologyReceptor PharmacologyReview Article Review Article 5-HT2Along-acting

Psilocybin's kinematic effect on manual dexterity.

RationaleClinical interest in psilocybin-assisted rehabilitation for motor disorders is growing. However, psilocybin's motor effects are under-researched, and quantifying them is essential for assessing treatment risks and outcomes.ObjectivesThis study aims to clarify whether acute effects of psilocybin disrupt established patterns of manual dexterity and co...

Unknown journal 2026-06-16 Klintefors P, Bhagavan C, Kanaan R, Bryson A, Berlowitz D, Attard Z, Carter O.
Europe PMC Published psilocybin Healthy VolunteersSafety Other

Anxiety-related platform in zebrafish (Danio rerio) larvae: An integrated analysis of behavioural and molecular assay in drug screening research.

Zebrafish larvae are increasingly used in behavioural pharmacology because of their translational relevance and suitability for anxiety- and stress-related studies. However, it remains unclear whether commonly used behavioural assays and molecular stress markers provide convergent evidence of anxiolytic-like drug activity. This study therefore aimed not to v...

Unknown journal 2026-06-16 Potoczna M, Kasica N, Chmielewska-Krzesińska M, Dybalska-Szczepanek J, Wąsowicz K, Sokołowska E, Podlasz P.
Europe PMC Published psilocybin AnxietyPharmacologyMechanism of ActionBiomarkers Other

Distinct brain responses to psilocybin and escitalopram in depression captured by the Fluctuation-Dissipation Theorem

In recent decades, the psychedelic psilocybin has been studied as a potential treatment for major depressive disorder (MDD), offering an alternative to traditional antidepressants. However, the brain changes underlying the clinical effects of different interventions remain unclear. Here, we investigated the effects of psilocybin and a conventional antidepres...

bioRxiv 2026-06-15 Dagnino PC, Acero-Pousa I, Zamora-López G, Escrichs A, Erritzoe D, Nutt DJ, Carhart-Harris RL, Sanz Perl Y, Kringelbach ML, Deco G.
bioRxiv PREPRINT (not peer reviewed) psilocybin DepressionBrain ImagingMechanism of ActionBiomarkersAgingRandomized Controlled Trial Randomized Controlled Trial

The Acute Effects of Psilocybin on Cognition, Memory, and Brain Function

This study will test the effects of psilocybin on memory and cognition in healthy participants using computerized tasks and magnetic resonance imaging (MRI). In a double-blind, placebo-controlled, repeated measures design in healthy participants, this study will test the effects of psilocybin on memory and cognition in healthy individuals using computerized ...

ClinicalTrials.gov 2026-06-14 Manoj Doss
ClinicalTrials.gov CLINICAL TRIAL psilocybin Brain ImagingAgingHealthy Volunteers Other HealthyPlacebo

Psilocybin-Assisted Psychotherapy for the Treatment of Severe Alcohol Use Disorder: A Double-Blind, Dose-Comparison Concurrent Control Randomized Trial

This study aims to determine the safety and preliminary efficacy of psilocybin-assisted psychotherapy in improving alcohol-related outcomes among adults with severe alcohol use disorder in a a double-blind, dose-comparison concurrent control, randomized trial. Participants will undergo structured psychotherapy and will be randomized to two psilocybin session...

ClinicalTrials.gov 2026-06-14 Brigham and Women's Hospital
ClinicalTrials.gov CLINICAL TRIAL psilocybin AnxietyAddictionBrain ImagingMechanism of ActionBiomarkersAgingEmotional ProcessingClinical TrialSafetyAdverse Events Clinical Trial Alcohol Use DisorderPsilocybin

Psilocybin and Mental Health Outcomes: Scoping Review with ☸️SAIMSARA

This scoping review aims to comprehensively map and synthesize the breadth of evidence from original research on the relationship between psilocybin and health, spanning clinical trials, epidemiological surveys, mechanistic experiments, and cross-sectional attitudinal studies. The review uses 145 references and builds its evidence map from 216 original studi...

SAIMSARA Journal 2026-06-14 Authors unavailable
Crossref Published psilocybin DepressionAnxietyPTSDAddictionEnd-of-Life DistressMechanism of ActionClinical TrialReview ArticleObservational StudyTreatment-Resistant DepressionSafety Clinical Trial

Efficacy of Psilocybin-Assisted Therapy in Major Depressive Disorder: A Systematic Review and Meta-Analysis

Background: This systematic review and meta-analysis evaluates the efficacy and safety of psilocybin-assisted psychotherapy (PAP) for adults with major depressive disorder (MDD). Methods: A PROSPERO-registered search (CRD42024561979) of CENTRAL, Scopus, PsycINFO, and MEDLINE (2010-2024) identified clinical trials assessing PAP. Risk of bias was assessed usin...

Psychiatry International 2026-06-14 Labra-Lorenzana Angel, Lima-Sánchez Dania Nimbe, Delaflor-Wagner Christian Alejandro, Martínez-Hernández Diana, Ramos-Jiménez Christian, Toledo-Lozano Christian Gabriel
Crossref Published psilocybin DepressionClinical TrialRandomized Controlled TrialMeta-AnalysisSystematic ReviewReview ArticleSafetyAdverse Events Randomized Controlled Trial

“I even saw four deer grazing”: online-offline entanglements in the psilocybin pluriverse

Purpose This paper aims to examine evolving practices and discourses surrounding psilocybin mushrooms on an online drug forum. Situating use within hybrid digital and ecological contexts, it traces shifts in user engagement before and after the 2020 COVID-19 pandemic to contextualize localized realities of the contemporary psychedelic renaissance. Design/met...

Drugs, Habits and Social Policy 2026-06-14 Wanke Michał, Matuszewski Paweł, Siuda Piotr
Crossref Published psilocybin AgingSafety Qualitative Study

Music Playlist Use in Clinical Trials of Psychedelic Assisted Psychotherapy: A Systematic Review.

Recent studies have shown promising results for psychedelics in the treatment of psychiatric disorders. Both in clinical and recreational settings, contextual elements, such as music, can influence the experience of users and may be linked to positive outcomes. This systematic review identifies how music is being selected and used in psychedelisc-assisted ps...

Unknown journal 2026-06-14 Cruz L, Beserra FR, Freind JMK, Rodrigues SE, Mograbi DC.
Europe PMC Published psilocybin DepressionPTSDClinical TrialSystematic ReviewReview Article Systematic Review

Unmixing the Psychedelic Connectome: Brain Network Traits of Psilocybin

Abstract Psilocybin induces profound alterations in consciousness, yet prevailing neural models often describe a monolithic change in brain connectivity that may not fully capture the multifaceted nature of the psychedelic state. To test the hypothesis of a composite neural state, this study applied a data-driven framework, Connectome Independent Component A...

Network Neuroscience 2026-06-13 Bhavaraju Kirshna Prasad, Mason Natasha L., Mallaroni Pablo, Heinke Dietmar, Toennes Stefan W., Ramaekers Johannes G., Amico Enrico
Crossref Published psilocybinpsilocin Brain ImagingConsciousnessHealthy Volunteers Other

Live source coverage

3,812 indexed records across 7 active sources.

3,046Published
479Preprints
287Clinical trials
  1. Europe PMC 2,654 records · 69.6%
  2. PubMed 309 records · 8.1%
  3. ClinicalTrials.gov 287 records · 7.5%
  4. PsyArXiv 218 records · 5.7%
  5. Crossref 168 records · 4.4%
  6. bioRxiv 142 records · 3.7%
  7. medRxiv 34 records · 0.9%

Counts exclude hidden records and curated false positives. Preprints remain labeled as not peer reviewed in search results and exports.